Biopharmaceutical company FibroGen, Inc. is a leading player in discovering, developing, and commercializing therapeutics aimed to address serious unmet medical needs. With a focus on its lead product candidates, the human monoclonal antibody Pamrevlumab and the oral small molecule inhibitor Roxadustat, FibroGen, Inc. is making strides in targeting conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, Duchenne muscular dystrophy, and anemia related diseases. The company's partnerships with Astellas Pharma Inc. and AstraZeneca AB are indicative of their willingness to collaborate with industry giants to further propel the success of their efforts. Established in 1993, FibroGen, Inc. is headquartered in San Francisco, California.